Junshi Bio (01877.HK) announced that its subsidiary, Jusgeno Bio, has signed a license and cooperation agreement with Gilead Sciences, granting Jusgeno Bio exclusive rights in the Greater China region to develop, improve, manufacture, produce, use, declare, register, commercialize, and utilize the IAMA-001 nasal spray project based on licensed intellectual property, and collaborate with Jusgeno Bio outside the Greater China region to develop the IAMA-001 nasal spray project.

Jusgeno Bio will pay Gilead Sciences an initial payment of 40 million RMB; and pay up to 0.24 billion RMB based on the progress of the licensed product research and development milestones in the Greater China region.